Company news
Upstream Bio, Inc. (NASDAQ:UPB) news
Every Upstream Bio, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress
August 11, 2026
Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Partic...
June 14, 2026
Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026
June 8, 2026
Upstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
June 3, 2026
Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participant...
May 18, 2026
Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 13, 2026
Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference
April 17, 2026
Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results
March 26, 2026
Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026...
March 1, 2026
Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Sessi...
February 26, 2026
Upstream Bio to Participate in Upcoming March Investor Conferences
February 25, 2026
Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma
February 11, 2026
Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma
February 10, 2026
Upstream Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 5, 2026
Upstream Bio to Participate in Upcoming December Investor Conferences
November 25, 2025
Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress
November 5, 2025
Upstream Bio to Participate in Upcoming November Investor Conferences
October 31, 2025
Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug’s Potent Pharmacodynamic Activity and Differentiated C...
September 30, 2025
Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum
September 9, 2025
Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis wi...
September 2, 2025
Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chr...
September 1, 2025
Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress
August 6, 2025
Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)
July 8, 2025
Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor
June 15, 2025
Upstream Bio to Present Mechanistic Insights into Verekitug’s Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy...
June 5, 2025
Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
June 4, 2025
Upstream Bio Appoints Stacy Price as Chief Technology Officer
May 20, 2025
Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs
May 6, 2025
Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
March 12, 2025
Upstream Bio to Present at Upcoming March Investor Conferences
February 25, 2025
Automotive Security Leaders Must Take Immediate Action to Mitigate the Surging Cyber Threats--Upstream Report Reveals Critical Gaps
February 11, 2025
Upstream Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 6, 2025
Upstream Bio Appoints Allison Ambrose as General Counsel
December 17, 2024
Upstream Bio Announces Addition to Russell 2000® Index
December 16, 2024
Upstream Bio to Participate in the Piper Sandler 36th Annual Healthcare Conference
November 21, 2024
Upstream Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights
November 7, 2024
Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purcha...
October 15, 2024